Denfivontinib

Denfivontinib (G-749) is a potent, oral active and ATP competitive FLT3 inhibitor, with IC50s of 0.4 nM and 0.6 nM for FLT3 wild type and FLT3-D835Y, respectively. Denfivontinib can be used for the research of agent resistance for acute myeloid leukemia (AML) [1].

Product Specifications

CAS Number

[1457983-28-6]

Product Name Alternative

G-749

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Apoptosis; FLT3

Type

Reference compound

Related Pathways

Apoptosis; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/denfivontinib.html

Purity

98.0

Solubility

DMSO : 25 mg/mL (ultrasonic)

Smiles

O=C1NC=C(C2=C1C(NC3=CC=C(C=C3)OC4=CC=CC=C4)=NC(NC5CCN(CC5)C)=N2)Br

Molecular Formula

C25H25BrN6O2

Molecular Weight

521.41

Precautions

H302, H315, H319, H335

References & Citations

[1]Lee HK, et al. G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia. Blood. 2014 Apr 3;123 (14) :2209-19.